Corporate Member Merck - EXPANDED INDICATION

Corporate Member Merck - EXPANDED INDICATION

KEYTRUDA (Pembrolizumab)
August, 2016

For Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy. 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members